Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alpine Immune Sciences Inc (NQ: ALPN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences Inc

< Previous 1 2 3 4 5 6 7 Next >
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc
Via Business Wire
Analyst Expectations for Alpine Immune Sciences's Future
Via Benzinga
Recap: Alpine Immune Sciences Q1 Earnings
Via Benzinga
Earnings Preview: Alpine Immune Sciences
Via Benzinga
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Earnings Scheduled For March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death
Via Benzinga
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
From Alpine Immune Sciences, Inc.
Via Business Wire
US Stock Futures Edge Higher; All Eyes On Fed Decision
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.